Neurotoxicity Clinical Trial
Official title:
Assessment of the Prognostic Value of Nerve Damage Biomarkers in Acute and Chronic Organophosphate Toxicity
The aim of this observational study is to answer the following questions in individuals with acute and chronic exposure to organophosphates. The main questions to be addressed are 1. What are the prognostic values of neuroinflammatory markers? 2. What are the genotoxic effects of organophosphates? 3. what are the changes occurring in the levels of traditional oxidative stress and inflammatory markers?
This is a cross-sectional study that aims to assess the possible prognostic value of markers of neuroinflammation and nerve damage in patients with acute and chronic exposure to organophosphate pesticides by conducting a full proteomic and metabolomic profile. The possible genotoxic effect of common organophosphate pesticides will be studied as well. This will be conducted in parallel to the assessment of traditional markers of inflammation and oxidative stress. The target populations are patients with acute and chronic exposure to organophosphates with a total estimated number of 90 including individuals assigned to the control group with matched age and gender. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05510596 -
Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome
|
N/A | |
| Completed |
NCT01399372 -
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
|
Phase 2 | |
| Completed |
NCT01196442 -
Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer
|
N/A | |
| Completed |
NCT00775645 -
S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy
|
Phase 3 | |
| Recruiting |
NCT00884767 -
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
|
Phase 2 | |
| Recruiting |
NCT03330964 -
Clinical Trial of Electroacupuncture Stimulation on Prevention and Treatment of Oxaliplatin Neurotoxicity
|
N/A | |
| Active, not recruiting |
NCT04150913 -
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
|
Phase 2 | |
| Completed |
NCT01417507 -
Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery
|
N/A | |
| Completed |
NCT00471445 -
Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients
|
Phase 3 | |
| Completed |
NCT00365768 -
Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors
|
Phase 2 | |
| Withdrawn |
NCT00734773 -
Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL
|
Phase 0 | |
| Completed |
NCT00305799 -
Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors
|
N/A | |
| Completed |
NCT00018967 -
Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate
|
N/A | |
| Active, not recruiting |
NCT00978458 -
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
|
Phase 3 | |
| Completed |
NCT05094154 -
Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
|
Phase 4 | |
| Completed |
NCT02486198 -
Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT05798884 -
Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients
|
N/A | |
| Completed |
NCT02864030 -
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
|
Phase 4 | |
| Completed |
NCT00755313 -
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
|
N/A | |
| Completed |
NCT00369564 -
Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer
|
Phase 3 |